2021 American Society of Hematology Annual Meeting*

Download All
December 11-14, 2021; Atlanta, Georgia
Expert faculty review and share their insights and perspectives on key findings in MDS and MPNs presented at the 2021 ASH Annual Meeting.
Amy E. DeZern, MD, MHS
Srdan Verstovsek, MD, PhD

Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Slidesets MANIFEST: Pelabresib (CPI-0610) Monotherapy in Patients With Myelofibrosis
Slidesets Phase Ib Study: Venetoclax/Azacitidine in Treatment-Naive Higher-Risk MDS
Slidesets PANTHER: Randomized Phase III Trial of First-line Pevonedistat + Azacitidine vs Azacitidine in Higher-Risk MDS/CMML or AML With 20% to 30% Marrow Blasts
Slidesets Phase II Trial of CPX-351 as First-line Treatment in Patients With Higher-Risk MDS
Slidesets Phase Ib Study of Sabatolimab + Hypomethylating Agents for Very High–Risk/High-Risk MDS and Newly Diagnosed AML: Final Analysis
Slidesets FIGHT-203: Phase II Trial of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Slidesets Phase II Trial of Rusfertide (PTG-300) in Patients With Phlebotomy-Dependent Polycythemia Vera
Slidesets Retrospective Analysis of Venetoclax + Hypomethylating Agents for Patients With Higher-Risk Myelodysplastic Syndromes
Slidesets Pilot Study of CPX-351 in Transplant-Eligible Patients With Previously Untreated Higher-Risk MDS
Slidesets Development and Validation of a Molecular International Prognostic Scoring System (IPSS-M) for MDS Risk Stratification
Slidesets Phase II Trial of Lenalidomide and Eltrombopag for Low-Risk/Intermediate-Risk MDS

Review expert perspectives on the most clinically relevant data on myelodysplastic syndromes and myeloproliferative neoplasms presented at the 2021 ASH Annual Meeting.

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: May 11, 2022 Expired: No longer available for credit
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings